This inventor holds 51 USPTO granted patents and 16 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in VEGF Antagonist Formulations. Top assignees: Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., Bristol-Myers Squibb Compnay. Active years: 1999-2025.
Location History:
- Durham, ND (US) (2005)
- New York, NY (US) (2009)
- Durham, NC (US) (1999 - 2011)
- Croton-on-Hudson, NY (US) (2004 - 2013)
- Concord, MA (US) (2009 - 2023)
- Lincoln, MA (US) (2019 - 2024)
Company Filing History:
17 out of 1,471 
14 out of 1,167 
8 out of 3,735 
Years Active: 1999-2025
Areas of Expertise:
Title: Eric Steven Furfine: Innovator in the Biomedical Field
Introduction: Eric Steven Furfine is a distinguished inventor based in Durham, North Carolina. With an impressive portfolio of 49 patents, Furfine has made significant contributions to the fields of biology and medicine, particularly in complement system modulation and therapeutic antibody development.
Latest Patents: Among his latest innovations are two notable patents. The first, titled "Complement Factor I-related compositions and methods," presents various Complement Factor I (CFI) variants that showcase improved characteristics compared to the wild type CFI. These variants exhibit tunable specificity and activity. The patent also details CFI-containing fusion constructs, which incorporate at least one domain of CFI, such as wild type full-length CFI fused to human serum albumin. The potential applications of these innovations include treatment for diseases associated with complement system dysregulation or a deficiency of CFI.
The second patent, "β-1,6-glucan therapeutic antibody conjugates," describes compositions where therapeutic antibodies are conjugated to β-1,6-glucan oligomers. This invention outlines methods for creating and utilizing these glucan conjugates, which may serve therapeutic purposes or be applied in treatment methods, enhancing therapeutic efficacy.
Career Highlights: Furfine has been associated with prominent companies in the pharmaceutical industry, including Regeneron Pharmaceuticals and Vertex Pharmaceuticals. His work at these institutions has contributed to the advancement of medical therapies and biotechnology.
Collaborations: Throughout his career, Furfine has collaborated with notable professionals such as Daniel B. Dix and Kenneth S. Graham. These collaborations have fostered innovative research and development in the biomedical sector.
Conclusion: Eric Steven Furfine exemplifies the spirit of innovation in the biomedical field, evidenced by his extensive patent portfolio and contributions to therapeutic developments. His work continues to influence advancements in treatments for diseases linked to the complement system and beyond.